NCT00009867View on ClinicalTrials.gov

Arsenic Trioxide in Treating Patients With Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

June 30, 2004

Conditions
Recurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerTransitional Cell Carcinoma of the BladderUreter Cancer
Interventions
DRUG

arsenic trioxide

Given IV

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00009867 - Arsenic Trioxide in Treating Patients With Urothelial Cancer | Biotech Hunter | Biotech Hunter